Carbonyl-Substituted Titanocene

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes novel carbonyl-substituted titanocene compounds and their use as pharmaceuticals, particularly for treating diseases characterized by rapidly proliferating (hyperproliferative) cells such as cancers and certain autoimmune or inflammatory conditions. These compounds can selectively induce apoptosis (programmed cell death) in malignant or abnormal cells, including those resistant to conventional therapies, while causing minimal harm to healthy cells. The patent also covers methods for the synthesis of these compounds and their use for diagnostic purposes.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of various cancers (e.g., leukemia, lymphomas, solid tumors, brain tumors)
• Therapy for therapy-resistant or recurrent tumors
• Treatment of benign hyperproliferative diseases (e.g., psoriasis, keloids)
• Adjunct or combination therapy with existing chemotherapeutic agents (especially nucleoside analogs like cytarabine)
• Antibacterial, antifungal, antiparasitic, antiviral, and immunosuppressive therapy
• Diagnostic marking and detection of rapidly proliferating cells in tissues or samples
• Preclinical and clinical research on apoptosis-inducing anticancer agents

BenefitsContent extracted from patent full text and abstract with AI.

• High selectivity toward rapidly proliferating abnormal cells, leading to reduced toxicity for healthy tissues
• Ability to induce apoptosis even in cells resistant to traditional chemo- or radiotherapies
• Potential to overcome drug resistance in various cancers, improving treatment outcomes
• Applicability in both malignant (cancer) and non-malignant (hyperproliferative) diseases
• Capability to cross the blood-brain barrier, enabling treatment of brain tumors
• Synergistic effects when combined with standard chemotherapeutics, enhancing efficacy
• Low unspecific cytotoxicity, resulting in better patient tolerability
• Can be used for diagnostic purposes, enabling precise detection of disease-related cell proliferation

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

Disclosed is a medicament containing a compound of formula (Ia) or (Ib), wherein Z is selected from among a group comprising a covalent bond, at least one at least bivalent heteroatom, a saturated, unsaturated, branched, linear and/or cyclic, substituted or unsubstituted hydrocarbon chain, a saturated or unsaturated, branched, linear and/or cyclic, substituted or unsubstituted hydrocarbon chain containing heteroatoms, or combinations thereof, R`1 to R`4 and R``1 to R``5 each independently represents H, at least one heteroatom, a saturated, unsaturated, branched, linear and/or cyclic, substituted or unsubstituted hydrocarbon chain, a saturated or unsaturated, branched, linear and/or cyclic, substituted or unsubstituted hydrocarbon chain containing heteroatoms, or combinations thereof, the cyclopentadienyl rings are optionally linked by means of any of the radicals R``1 to R``5, R1 and R2 independently represent H, a heteroatom, a saturated, unsaturated, branched, linear and/or cyclic, substituted or unsubstituted hydrocarbon chain, a saturated or unsaturated, branched, linear and/or cyclic, substituted or unsubstituted hydrocarbon chain containing heteroatoms, or combinations thereof, A`, A`` independently represent F, Cl, BR, I, and/or a physically acceptable acid radical of an organic or inorganic acid, n represents a positive integer, particularly 1, 2, 3, X = O, S, NH, NR3, NR4R5, wherein R3, R4, and R5 independently have the meanings indicated for R`1 to R`4, Y = a covalent bond, O, S, or NR6, wherein R6 has the meaning indicated for R`1 to R`4.